Welcome to our dedicated page for COMPUGEN SEC filings (Ticker: CGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on COMPUGEN's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into COMPUGEN's regulatory disclosures and financial reporting.
Compugen Ltd. director Mathias Hukkelhoven reported equity awards dated July 29, 2026. He received options for 10,000 Ordinary Shares at an exercise price of $2.2600, expiring July 29, 2036, and an RSU award for 7,500 shares. Both awards vest 25% on October 1, 2027, with the remainder in 12 equal quarterly installments, subject to continued service. Following the RSU grant, he directly holds 17,500 Ordinary Shares.
COMPUGEN LTD director Halevy Gilead received new equity awards on July 29, 2026. The grants consist of 7,500 restricted stock units and a share option for 10,000 ordinary shares at an exercise price of $2.26 per share, expiring July 29, 2036. Both the RSUs and the option vest 25% on October 1, 2027, with the remaining 75% vesting in 12 equal quarterly installments, subject to continued service. After these awards, Gilead directly holds 18,907 ordinary shares and options for 10,000 shares.
Compugen Ltd director Sanford S. Zweifach received equity-based compensation on July 29, 2026. He was granted 7,500 restricted stock units and a share option for 10,000 ordinary shares at an exercise price of $2.26. Both awards vest 25% on October 1, 2027 and the remainder in 12 equal quarterly installments, subject to continued service. Following these awards he directly holds 20,180 ordinary shares and 10,000 options.
Compugen Chief Medical Officer Michelle Mahler received equity awards on July 29, 2026, consisting of 13,500 restricted stock units and a stock option for 18,000 ordinary shares at an exercise price of $2.26 per share. Both awards vest 25% on September 30, 2027, with the remainder in 12 equal quarterly installments, subject to her continued service. Following the RSU grant, she directly holds 36,625 ordinary shares.
Compugen Ltd senior vice president of business development Zurit Levine exercised options to acquire 1,875 Ordinary Shares at $0.8292 per share and, on the same date, sold 1,875 Ordinary Shares at $2.50 per share in an open-market transaction. The trades were made pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025. Following these transactions, Levine directly holds 29,375 Ordinary Shares and 3,750 share options with a $0.8292 exercise price expiring on November 9, 2032.
Compugen Ltd. files a shelf registration to offer up to $400,000,000 of securities, including a sales agreement allowing up to $100,000,000 of ordinary shares to be sold under an at-the-market sales agreement with Leerink Partners LLC. The base prospectus covers ordinary shares, debt securities, rights, warrants and units in one or more offerings from time to time after effectiveness. The prospectus notes our ordinary shares trade on Nasdaq and the Tel Aviv Stock Exchange (symbol CGEN) and discloses a closing sale price of $3.03 (Nasdaq) and NIS 8.361 ($2.88 equivalent) on May 14, 2026. The prospectus also summarizes business operations, clinical programs and a March 31, 2026 capitalization table that shows cash and investments and issued ordinary shares.
Compugen Ltd. reported first quarter 2026 results, highlighting steady clinical progress and a solid balance sheet. Revenue was $2.2 million, slightly below the prior year, mainly from recognition of upfront and milestone payments under its Gilead license agreement.
The company recorded a net loss of $7.7 million, or $0.08 per share, similar to the prior-year loss, as increased R&D spending of $6.9 million supported its MAIA-ovarian trial and other programs. General and administrative expenses were stable at $2.3 million.
Compugen ended March 31, 2026 with $134.9 million in cash, cash equivalents, short-term deposits and marketable securities and reported no debt, stating this cash is expected to fund operations into 2029. Management emphasized progress in its immuno-oncology pipeline and noted up to $1 billion in potential milestones plus royalties from partnerships with AstraZeneca and Gilead.
Compugen Ltd SVP of Business Development Zurit Levine exercised options and sold shares in a pre-planned transaction. On April 24, 2026, she exercised 2,000 share options at $1.15 per share and sold 2,000 ordinary shares at $3.20 per share in an open-market sale pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025. Following these transactions, she directly held 29,375 ordinary shares.
Compugen Ltd President and CEO Ophir Eran reported an exercise-and-sale transaction in the company’s Ordinary Shares. On April 24, 2026, he exercised options to acquire 5,000 shares at an exercise price of $0.8292 per share and sold 5,000 shares in open-market trades at a weighted average price of $3.2001 per share. Following these transactions, he directly holds 11,375 Ordinary Shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025.